Lonza maintains 2017 target and says US plant and Capsugel integration on track

By Gareth Macdonald contact

- Last updated on GMT

Lonza's Visp facility (Source Lonza website)
Lonza's Visp facility (Source Lonza website)

Related tags: Future, Cell culture, Revenue

Lonza has reaffirmed its full-year sales and earnings forecast and updated about its US operations and the integration of Capsugel.

The Swiss life sciences supplier confirmed its 2017 prediction this week, explaining it expects full year revenue to grow in the high single digits and core EBITDA to be over CHF1bn. In 2016, sales were CHF4.13bn and EBITDA was CHF918m.

Lonza made the comments in a third quarter business update, which also touched on the performance of its segments - Pharma&Biotech and Specialty Ingredients – but did not provide specific revenue and earnings figures.

Pharma&Biotech continued its momentum in Q3 2017; however, results are compared with an exceptionally strong Q3 2016​” according to the firm, adding that its mammalian cell culture based and chemical manufacturing activities had been performance drivers.

Similarly, Lonza said its specialty ingredients business – which makes products for the consumer care, agro, coatings, composites and water treatment industries – “experienced a solid Q3 2017 and performed as expected.”

Manufacturing plant

Lonza has more specific about its manufacturing facilities.

It made clear that “hurricanes in the US Southeast had no material impact on the company's overall performance as operational issues were resolved thanks to the efforts of the managers and employees in these regions​.”

It also confirmed the cell and gene therapy facility it is building in Pearland in Houston, Texas is on track to become operational early next year.

Pharma&biotech outlook

Lonza was positive about the future performance of it pharma&biotech business, although again it did not provide figures.

The firm said its new Ibex offering – which has seen it set up dedicated manufacturing capacity for Sanofi and Portola at its facility in Visp, Switzerland – and recent acquisition Capsugel will drive growth.

In Q3 2017 Capsugel performed in line with expectations with particularly strong results in Consumer Health and Nutrition,​” Lonza said.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars